References
- TsiligianniIKocksJTzanakisNSiafakasNvan der MolenTFactors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlationsPrim Care Respir J201120325726821472192
- Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [updated 2016]. Available from: http://goldcopd.org/gold-reports/Accessed April 28, 2016
- D’UrzoADRennardSIKerwinEMMergelVLeselbaumARCaractaCFEfficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD studyRespir Res201415112314125756831
- SinghDJonesPWBatemanEDEfficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised studyBMC Pulm Med201414117818925404569
- BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
- DonohueJFMaleki-YazdiMRKilbrideSMehtaRKalbergCChurchAEfficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPDRespir Med2013107101538154623830094
- MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
- LeidyNKSextonCCJonesPWMeasuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diaryThorax201469544344924595666
- LeidyNKMurrayLTMonzBUMeasuring respiratory symptoms of COPD: performance of the EXACT-Respiratory Symptoms Tool (E-RS) in three clinical trialsRespir Res201415112425287629
- JonesPWLeidyNKHareendranALamarcaRChuecosFGarcia GilEThe effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the evaluating respiratory symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studiesRespir Res20161716127215749
- MahlerDAWeinbergDHWellsCKFeinsteinARThe measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexesChest19848567517586723384
- European Medicines AgencyDuaklir Genuair [updated June 21, 2016]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003745/human_med_001811.jsp&mid=WC0b01ac058001d124Accessed July 11, 2016
- MahlerDAKerstjensHADonohueJFBuhlRLawrenceDAltmanPIndacaterol vs tiotropium in COPD patients classified as GOLD A and BRespir Med201510981031103926094050
- BatemanEDChapmanKRSinghDAclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multi-centre, randomised studies (ACLIFORM and AUGMENT)Respir Res2015169226233481
- MiravitllesMWorthHSoler CatalunaJJObservational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS studyRespir Res20141512225331383
- PartridgeMRKarlssonNSmallIRPatient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet surveyCurr Med Res Opin20092582043204819569976
- MiravitllesMWorthHSoler-CatalunaJJThe relationship between 24-hour symptoms and COPD exacerbations and healthcare resource use: results from an observational study (ASSESS)COPD201618
- MiravitllesMFerrerJBaroELleonartMGaleraJDifferences between physician and patient in the perception of symptoms and their severity in COPDRespir Med2013107121977198523890959
- RennardSDecramerMCalverleyPMImpact of COPD in North America and Europe in 2000: subjects’ perspective of confronting COPD International SurveyEur Respir J200220479980512412667